Health & Growth

Health is at the heart of Europe’s economic and social prosperity. Efpia believes Europe needs an integrated life science strategy for the EU. Towards that end, our industry is committed to partnering with all stakeholders to:

                                                    Click to enlarge

Better Health Outcomes

Europe has made huge strides in improving life expectancy and overall health over the last 50 year… but major inequalities persist.

Improving  Health Outcomes 

  • Priorities: Europe needs to remain healthy and productive by improving health outcomes in chronic and non-communicable diseases
  • Ambition: Increase healthy life years and reduce hospitalisation rates in chronic disease by 10% by 2020

Reducing Inequalities 

  • Priorities: Europe needs to address inequalities in access to health services especially medicines
  • Ambition: Ensure that each EU citizen has the same level of access to innovative medicines
                                                    Click to enlarge

Sustainable Financing

Appropriate use of medicines is  a critical tool for sustainable healthcare financing in Europe… but access and predictability of funding has to be improved.

Advancing Patient Access 

  • Priorities: Europe needs to accelerate access to new medicines. National authorities should develop a harmonised approach to medicines’ assessment
  • Ambition: National authorities should adopt a single approach to assess the value of medicines and reduce delays to market access 

Fostering  Growth & Stability

  • Priorities: Europe needs to encourage the use of ‘Growth and Stability Frameworks’ to secure appropriate funding for medicines
  • Ambition: Medicines expenditure should grow at least in line with overall healthcare expenditure
Click to enlarge

Thriving Eco-System

The research-based pharmaceutical industry continuously invests in R&D… but Europe is losing its competitiveness in the fight for R&D investments. 

Leadership in Health Research

  • Priorities : Europe needs to establish a long-term and coherent research and innovation agenda in life sciences and commit to academic excellence
  • Ambition : Within 10 years, Europe should re-establish parity with the US as a source of new innovation in life science

Incentives for Innovation

  • Priorities : Europe needs to institute a more flexible and supportive system of incentives, fit for next-generation biomedical innovation
  • Ambition :  Europe should have the most advanced Intellectual Property (‘IP’) environment that supports modern science in areas of healthcare priority

Now is the time for science, society and decision-makers to work together to tackle these issues and build healthier future for Europe and its citizens. 




1) United Nations’ global development network: Human Development Report  (access 2013) 
2) OECD Health Statistics Database (accessed 2013); Eurostat Database (accessed 2013); 17 EU OECD Countries, population-weighted, current prices, PPP, $; Countries included: AT, BE, CZ, DK, FI, FR, DE, HU, IE, IT, LU, NL, PO, PT, SK, ES, SE 
3) EFPIA: Pharmaceutical industry in figures (2013); Note: R&D intensity gain/loss calculated as difference between average R&D intensity in 1995-2000 and 2001-2006